D
Dolf Boerman
Publications - 4
Citations - 971
Dolf Boerman is an academic researcher. The author has contributed to research in topics: Lomustine & Bevacizumab. The author has an hindex of 4, co-authored 4 publications receiving 838 citations.
Papers
More filters
Journal ArticleDOI
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Walter Taal,HM Oosterkamp,Annemiek M E Walenkamp,Hendrikus J. Dubbink,Laurens V. Beerepoot,Monique Hanse,Jan Buter,Aafke H. Honkoop,Dolf Boerman,Filip de Vos,Winand N.M. Dinjens,Roelien H. Enting,Martin J B Taphoorn,Franchette W P J van den Berkmortel,Rob L. H. Jansen,Dieta Brandsma,Jacoline E C Bromberg,Irene van Heuvel,René M. Vernhout,Bronno van der Holt,Martin J. van den Bent +20 more
TL;DR: The first randomised controlled phase 2 trial of bevacizumab in recurrent glioblastoma reported overall survival at 9 months, and the combined treatment was well tolerated.
Journal ArticleDOI
Cognitive Rehabilitation in Patients With Gliomas: A Randomized, Controlled Trial
Karin Gehring,Margriet M. Sitskoorn,Chad M. Gundy,Sietske A.M. Sikkes,Martin Klein,Tjeerd J. Postma,Martin J. van den Bent,Guus Beute,Roelien H. Enting,Arnoud C. Kappelle,Willem Boogerd,Theo Veninga,Albert Twijnstra,Dolf Boerman,Martin J B Taphoorn,Neil K. Aaronson +15 more
TL;DR: The CRP has a salutary effect on short-term Cognitive complaints and on longer-term cognitive performance and mental fatigue and additional research is needed to identify which elements of the intervention are most effective.
Journal ArticleDOI
A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study.
Walter Taal,HM Oosterkamp,Annemiek M E Walenkamp,Laurens V. Beerepoot,Monique Hanse,Jan Buter,Aafke H. Honkoop,Dolf Boerman,Filip de Vos,Rob L. H. Jansen,Franchette W P J van den Berkmortel,Dieta Brandsma,Johan M. Kros,Jacoline E C Bromberg,Irene van Heuvel,Marion Smits,Bronno van der Holt,René M. Vernhout,Martin J. van den Bent +18 more
TL;DR: Patients with histologically proven glioblastoma, with a first recurrence after chemo-irradiation with temozolomide, having concluded radiotherapy more than 3 months ago, with adequate bone marrow, renal and hepatic function, and WHO performance status (PS) 0-2 are enrolled.
Journal ArticleDOI
O10.05final analysis of the belob trial (a randomized phase ii study on bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma) and first radiology review results
Walter Taal,HM Oosterkamp,Annemiek M E Walenkamp,Hendrikus J. Dubbink,Laurens V. Beerepoot,Monique Hanse,Jan Buter,Aafke H. Honkoop,Dolf Boerman,F. Y. F. Vos,Winand N.M. Dinjens,Roelien H. Enting,M. J. B. Taphoorn,F. W. P. J. van den Berkmortel,Rob L. H. Jansen,Dieta Brandsma,Jacoline E C Bromberg,I. van Heuvel,René M. Vernhout,B. van der Holt,M. J. van den Bent +20 more
TL;DR: The combination bevacizumab/lomustine warrants further investigation, and is currently investigated in the randomized controlled phase III EORTC trial 26101.